Alberto Orfao is an expert in Hematology at Centro de Investigación del Cáncer (Spain). As of October 2026, ScienceLeadR ranks Alberto Orfao in the top 1% of experts worldwide for Leukemia, Hemostatic Disorders and Paraproteinemias. Alberto Orfao has authored 1,008 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 3,555 (community average: 125). How the SLR is computed.

LeadR Profile

3 555 ScienceLeadR Reputation 3555
Network Map

Hematology

Subspecialties: Immunology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1988 - 2026

Source: PubMed

University of Salamanca

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1008

Citations

Citations: 76 036 1st author: 27 Last author: 265 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Mast cell activation syndrome: Global perspectives from a World Allergy Organization survey on knowledge, diagnosis, and access to care.
PMID 42857128 — cells, research design, laboratories, hypersensitivity, uncertainty, biomarkers, allergists, diagnosis, mast cells, mast cell activation syndrome, allergy
World Allergy Organ J20260
Comprehensive genetic characterization of adult BCR::ABL1-negative B-ALL by Optical Genome Mapping and Targeted NGS.
PMID 42664485 — burkitt lymphoma, precursor cell lymphoblastic leukemia-lymphoma, workflow, genome, prevalence, mutation, hematologic diseases
Blood Adv20260
Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B-cell acute lymphoblastic leukemia: A report from The Cytometry Society, India.
PMID 42549678 — cells, flow cytometry, precursor cell lymphoblastic leukemia-lymphoma, laboratories, leukemia, b-lymphocytes
Cytometry B Clin Cytom20260
Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies.
PMID 42471331 — cells, bone marrow, plasma cells, phenotype, waldenstrom macroglobulinemia, b-lymphocytes, plasma
Blood Cancer J20260
Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).
PMID 42339339 — genes, myelodysplastic syndromes, multiple chronic conditions, classification, therapeutics, loss of heterozygosity, rna
Hemasphere20261

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3
N/A 2
Phase 2 2

By status:

Completed 5
Active not recruiting 1
Recruiting 1

By type:

Interventional 6
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study of the Infusion of ARI 0001 Cells in Patients With CD19 Acute Lymphoid Leukemia Resistant or Refractory to Therapy
NCT04778579 — cells, precursor cell lymphoblastic leukemia-lymphoma, blood, lymphoma, leukemia, leukemia, lymphoid, receptors, antigen, receptors, chimeric antigen, therapeutics, lentivirus
Phase 2Active not recruiting2021

LeadR Networks

Main global connection map